Peter Lynch · Growth at a reasonable price (GARP)
Is Xeris Biopharma Holdings, Inc. (XERS) a Peter Lynch Stock?
Strong GARP candidate: growth at a reasonable price.
84/100
Mitigé
3/6 critères validés
Les critères de Peter Lynch, appliqués à XERS
PEG ≤ 1.0
clé-
EPS CAGR ≥ 15%
clé-
Revenue CAGR ≥ 10%
55.8%
Net margin > 0
3.8%
Comment XERS se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$1.66B
PER (TTM)
92.7x
ROIC (TTM)
12.84%
Marge brute
81.59%
Autres analyses Peter Lynch
Questions fréquentes
What is XERS's Peter Lynch fit score?
XERS scores 84/100 on our Peter Lynch fit engine. Strong GARP candidate: growth at a reasonable price.
Does Peter Lynch actually own XERS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends XERS.
How often is this score updated?
XERS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande XERS personnellement.
